Diamyd partners its diabetes vaccine with J&J unit
Diamyd Medical AB has partnered its lead antigen-based therapy for the treatment and prevention of Type1 diabetes with Ortho-McNeil-Janssen Pharmaceuticals Inc (OMJPI), a unit of Johnson & Johnson.
News
Commentary: Europe has the power to harmonise HTA data, but will it do so?
Experts say that existing European law permits the establishment of common criteria for determining the relative effectiveness of licensed drugs. But will it happen?
Sanofi and Regulus form microRNA alliance
Sanofi-Aventis SA and Regulus Therapeutics Inc have formed a global alliance to develop and commercialise medicines based on microRNA, a class of small ribonucleic acid molecules that regulate gene expression.
FDA approves first diagnostic for HIV antigen and antibodies
The US Food and Drug Administration said that it has approved the first diagnostic assay to detect both antigen and antibodies to the Human Immunodeficiency Virus (HIV). Most current tests detect HIV antibodies only.
Pharma cuts capacity, but the pendulum can’t swing too far – Andrew Witty
Despite downward pressure on drug prices, Big Pharma needs to keep enough research capacity in the system so that it can produce the medicines that patients will need in the future, according to Andrew Witty, chief executive officer of GlaxoSmithKline, and incoming president of the European Federation of Pharmaceutical Industries and Associations (Efpia).
Alliance formed to research anti-cancer stem cell therapies
OncoMed Pharmaceuticals Inc of California and Bayer Schering Pharma AG of Berlin have entered into a global alliance to develop therapies that attack cancer stem cells.
Clinical trial data likely to be made public
Regulatory authorities in the US and Europe are taking steps to make more clinical trial data available to the public, possibly including information on the results of these trials, speakers at the Drug Information Association said on 16 June 2010
Initial public offering under way for artificial heart company
An initial public offering for Carmat SAS, which makes artificial hearts, is under way on the Alternext section of the NYSE-Euronext exchange in Paris.
FDA approves prostate treatment from GSK
GlaxoSmithKline said that the US Food and Drug Administration has approved its combination treatment for benign prostatic hyperplasia, Jalyn. The drug combines dutasteride and tamsulosin in a single capsule.
Genmab’s chief executive retires
Genmab A/S, which develops antibodies for cancer, announced on 15 June 2010 the retirement of its chief executive, Lisa Drakeman, who has served in that post since the Danish company was founded in 1999.